Müller-Tidow C - Search Results

1

Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.

Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, Noppeney R, Schäfer-Eckart K, Wendelin K, Mikesch JH, Middeke JM, Reimann M, Fiebig F, Zukunft S, Wermke M, Serve H, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M. Röllig C, et al. Among authors: muller tidow c. Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19436. Online ahead of print. Br J Haematol. 2024. PMID: 38593353

2

Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer.

Müller-Tidow C, Kügler K, Diederichs S, Klümpen S, Möller M, Vogt U, Metzger R, Schneider PM, Berdel WE, Serve H. Müller-Tidow C, et al. Br J Cancer. 2001 Oct 19;85(8):1168-74. doi: 10.1054/bjoc.2001.2041. Br J Cancer. 2001. PMID: 11710831 Free PMC article.

3

Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.

Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, Büchner T, Kessler T, Herrera F, Kienast J, Müller-Tidow C, Serve H, Berdel WE, Mesters RM. Padró T, et al. Leukemia. 2002 Jul;16(7):1302-10. doi: 10.1038/sj.leu.2402534. Leukemia. 2002. PMID: 12094254 Clinical Trial.

4

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Böhmer FD, Müller-Tidow C, Berdel WE, Serve H. Mizuki M, et al. Blood. 2003 Apr 15;101(8):3164-73. doi: 10.1182/blood-2002-06-1677. Epub 2002 Dec 5. Blood. 2003. PMID: 12468433 Free article.

5

Cyclin A1 is highly expressed in aggressive testicular germ cell tumors.

Müller-Tidow C, Diederichs S, Schrader MG, Vogt U, Miller K, Berdel WE, Serve H. Müller-Tidow C, et al. Cancer Lett. 2003 Feb 10;190(1):89-95. doi: 10.1016/s0304-3835(02)00582-7. Cancer Lett. 2003. PMID: 12536081

6

Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.

Steffen B, Serve H, Berdel WE, Agrawal S, Linggi B, Büchner T, Hiebert SW, Müller-Tidow C. Steffen B, et al. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8448-53. doi: 10.1073/pnas.1330293100. Epub 2003 Jun 20. Proc Natl Acad Sci U S A. 2003. PMID: 12819347 Free PMC article.

7

Redirection of oncoproteins to kill cancer cells.

Müller-Tidow C, Steffen B, Berdel WE, Serve H. Müller-Tidow C, et al. Cell Cycle. 2003 Nov-Dec;2(6):531-3. doi: 10.4161/cc.2.6.585. Cell Cycle. 2003. PMID: 14504468 Review.

8

E- and A-type cyclins as markers for cancer diagnosis and prognosis.

Yasmeen A, Berdel WE, Serve H, Müller-Tidow C. Yasmeen A, et al. Expert Rev Mol Diagn. 2003 Sep;3(5):617-33. doi: 10.1586/14737159.3.5.617. Expert Rev Mol Diagn. 2003. PMID: 14510182 Review.

9

Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.

Tiesmeier J, Czwalinna A, Müller-Tidow C, Krauter J, Serve H, Heil G, Ganser A, Verbeek W. Tiesmeier J, et al. Br J Haematol. 2003 Nov;123(3):413-9. doi: 10.1046/j.1365-2141.2003.04618.x. Br J Haematol. 2003. PMID: 14616999 Free article.

10

Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.

Tiesmeier J, Müller-Tidow C, Westermann A, Czwalinna A, Hoffmann M, Krauter J, Heil G, Ganser A, Serve H, Verbeek W. Tiesmeier J, et al. Leuk Res. 2004 Oct;28(10):1069-74. doi: 10.1016/j.leukres.2004.02.009. Leuk Res. 2004. PMID: 15289019

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

507 results

Search Page